{"symbol":"GILD","fiscalQuarter":"Q3-2013","reportDate":"2013-10-29","reportTime":"AMC","status":"reported","company":{"name":"Gilead Sciences, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/GILD/earnings/Q3-2013","postBrief":{"headline":"Gilead Sciences Beats on EPS, Stock Down N/A%","keyNumbers":[{"metric":"EPS","actual":"$0.52","expected":"N/A","surprise":"+10.64%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the strong performance in their key therapeutic areas.","They expressed confidence in their pipeline but acknowledged market challenges."],"summary":"Overall, management conveyed a positive outlook regarding their product performance while remaining aware of potential market headwinds."},"guidanceChanges":{"summary":"No guidance updates were provided during the call.","changes":[]},"whatItMeans":"Gilead Sciences reported better-than-expected earnings per share, indicating strong operational performance. However, the lack of revenue data and guidance may leave investors cautious. The stock's reaction is currently unavailable, reflecting uncertainty in market sentiment.","metaDescription":"Gilead Sciences (GILD) Q3 2013 earnings: EPS beat by 10.64%. Stock reaction unavailable. Full breakdown."}}